Pozelimab
CHAPLE Disease
Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the CHAPLE Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →